WELCOME

CARUGO - POMPILIO GROUP

WHAT THE CARUGO - POMPILIO GROUP DOES?

The applied research activity of CERCA aims to understand pathogenesis and innovative diagnostic and therapeutic strategies for cardiovascular diseases, in particular heart failure of genetic or ischemic origin (with specific focus on regenerative medicine), for which conventional therapies are either not sufficient or not available.

The team is composed by Prof. Pompilio, Prof. Carugo, five physicians, one geneticist, one research staff, seven post-docs, two laboratory technicians and a clinical research assistant.

WHAT SERVICE DO WE OFFER?

Besides a solid experience in the diagnosis and treatment of heart diseases and cardiomyopathies, the group is involved in clinical and translational research.

Our projects are based on novel patient-specific cellular models, which allow the study of pathogenic alterations, underlying molecular mechanisms and constitute a cellular platform for drug screening. In addition to the use of primary cells, several human induced pluripotent-derived cell lines (hu iPSC) were produced and characterized, from which cardiomyocytes were obtained.

Patients constitute the starting and closing point of CERCA studies. For this reason, a complete clinical and genetic characterization of patients is important.

This is made possible through dedicated cardiomyopathy outpatient services, first and second level echocardiography as well as Magnetic Resonance Imaging.

A genetic diagnostic service for cardiomyopathies is also active with Next Generation Sequencing technology.

PUBLICATIONS CARUGO - POMPILIO GROUP

DONATION CARUGO - POMPILIO GROUP

 Your donation for: Give your help to research on cardiomyopathies. Donate to CERCA CERCA PROJECT Given the accessibility to human biological samples of patients with different cardiac genetic disorders, and the expertise gained in the isolation and characterization of cell lines as disease models, CERCA is will implement a repository of biopsy samples, cellular lines derived from patients, and associated data. In particular: - The pathologies of interest are cardiomyopathies (arrhythmogenic, dilated, hypertrophic, restrictive), channelopathies (Brugada, long QT, CPVT), muscular dystrophies with cardiac involvement (Duchenne, Becker), neuromuscular disease with cardiac involvement (myotonic dystrophy, neurofibromatosis) and aortic disorders (Marfan). - Starting samples are skin biopsies, cardiac biopsy, aorta biopsies, whole blood, nucleated blood component, plasma, serum and patient urine. - The stored cell lines are skin fibroblasts, mesenchymal stromal cells, smooth vascular muscle cells, stromal mesenchymal cells from subcutaneous fat tissue, mononuclear cells of the blood, kidney epithelial cells. - Each donor patient is well characterized clinically and genetically and selected for genetic cause and lack of comorbidities. - The iPSCs are characterized by morphology of colonies, expression of pluripotency markers, karyotype, differentiation capability into the three embryonic tissue layers and absence of mycoplasma. For each line of iPSCs, a corresponding line may be created where the causative mutation is genetically corrected. From the iPSC lines it will be possible to obtain cells differentiated into cardiomyocytes, stromal or endothelial cells. This repository is an essential research tool for the CERCA and a major collaborative platform. You can make your donation by bank transfer to the following references or via Paypal.
DONATE NOW

Visit other groups in the Pediatric Clinical Research Center

Pediatric Clinical Research Center  Romeo and Enrica Invernizzi | Privacy and Terms Website | Webmaster Andrea Panigada